Author details

Full Name

H-J Su Huang

Affiliation

Regeneron Pharmaceuticals Inc.

ORCID

Career Start Year

1994

Papers

H Index

Expertise

CM4AI Collaborator

PMID	Paper Title	Journal Title	Published Year
37058568	IL-6-GP130 signaling protects human hepatocytes against lipid droplet accumulation in humanized liver models.	Sci Adv	2023
35928912	Effect of Recombinant Netrin-1 Protein Combined with Peripheral Blood Mesenchymal Stem Cells on Angiogenesis in Rats with Arteriosclerosis Obliterans.	Biomed Res Int	2022
36204132	rhCNB Improves Cyclophosphamide-Induced Immunodeficiency in BALB/c Mice.	Evid Based Complement Alternat Med	2022
20660366	KLF6 Gene and early melanoma development in a collagen I-rich extracellular environment.	J Natl Cancer Inst	2010
12861074	Angiopoietin-2 induces human glioma invasion through the activation of matrix metalloprotease-2.	Proc Natl Acad Sci U S A	2003
12651601	Platelet-derived growth factor-B enhances glioma angiogenesis by stimulating vascular endothelial growth factor expression in tumor endothelia and by promoting pericyte recruitment.	Am J Pathol	2003
11770895	CD95-mediated apoptosis of human glioma cells: modulation by epidermal growth factor receptor activity.	Brain Pathol	2002
12438278	Mutant epidermal growth factor receptor signaling down-regulates p27 through activation of the phosphatidylinositol 3-kinase/Akt pathway in glioblastomas.	Cancer Res	2002
12065666	A novel seven transmembrane receptor induced during the early steps of astrocyte differentiation identified by differential expression.	J Neurochem	2002
11920591	Novel monoclonal antibody specific for the de2-7 epidermal growth factor receptor (EGFR) that also recognizes the EGFR expressed in cells containing amplification of the EGFR gene.	Int J Cancer	2002
11164186	Aberrant receptor signaling in human malignant gliomas: mechanisms and therapeutic implications.	Cancer Lett	2001
11565870	Human glioblastoma xenografts overexpressing a tumor-specific mutant epidermal growth factor receptor sensitized to cisplatin by the AG1478 tyrosine kinase inhibitor.	J Neurosurg	2001
11454674	Monoclonal antibody 806 inhibits the growth of tumor xenografts expressing either the de2-7 or amplified epidermal growth factor receptor (EGFR) but not wild-type EGFR.	Cancer Res	2001
11454673	Growth suppression of intracranial xenografted glioblastomas overexpressing mutant epidermal growth factor receptors by systemic administration of monoclonal antibody (mAb) 806, a novel monoclonal antibody directed to the receptor.	Cancer Res	2001
11388668	The potential of TRAIL for cancer chemotherapy.	Apoptosis	2001
11514572	The protein tyrosine phosphatase TCPTP suppresses the tumorigenicity of glioblastoma cells expressing a mutant epidermal growth factor receptor.	J Biol Chem	2001
10706092	Increased death receptor 5 expression by chemotherapeutic agents in human gliomas causes synergistic cytotoxicity with tumor necrosis factor-related apoptosis-inducing ligand in vitro and in vivo.	Cancer Res	2000
11302255	SETA: a novel SH3 domain-containing adapter molecule associated with malignancy in astrocytes.	Neuro Oncol	2000
10896202	Analysis of the p300/CBP-Associated Factor (PCAF) gene in astrocytic tumors.	J Neurooncol	2000
10890917	A peptide derived from the non-receptor-binding region of urokinase plasminogen activator inhibits glioblastoma growth and angiogenesis in vivo in combination with cisplatin.	Proc Natl Acad Sci U S A	2000
10554042	Expression of the Ets-1 transcription factor in human astrocytomas is associated with Fms-like tyrosine kinase-1 (Flt-1)/vascular endothelial growth factor receptor-1 synthesis and neoangiogenesis.	Cancer Res	1999
10446968	The chromosome 10 monosomy common in human melanomas results from loss of two separate tumor suppressor loci.	Cancer Res	1999
11504467	Causes of drug resistance and novel therapeutic opportunities for the treatment of glioblastoma.	Drug Resist Updat	1999
10197615	Induction of vascular endothelial growth factor expression in endothelial cells by platelet-derived growth factor through the activation of phosphatidylinositol 3-kinase.	Cancer Res	1999
10074901	Malignant transformation of p53-deficient astrocytes is modulated by environmental cues in vitro.	Cell Growth Differ	1999
10494560	Expression of integrin transcripts in human cancer cells.	Methods Mol Biol	1999
10527883	Identification and validation of tumor suppressor genes.	Mol Cell Biol Res Commun	1999
9823298	The phosphoinositol phosphatase activity of PTEN mediates a serum-sensitive G1 growth arrest in glioma cells.	Cancer Res	1998
9661881	Absence of PTEN/MMAC1 germ-line mutations in sporadic Bannayan-Riley-Ruvalcaba syndrome.	Cancer Res	1998
9576951	Drug resistance of human glioblastoma cells conferred by a tumor-specific mutant epidermal growth factor receptor through modulation of Bcl-XL and caspase-3-like proteases.	Proc Natl Acad Sci U S A	1998
9829808	Expression of vascular endothelial growth factor in human brain tumors.	Acta Neuropathol	1998
9689095	In vitro loss of heterozygosity targets the PTEN/MMAC1 gene in melanoma.	Proc Natl Acad Sci U S A	1998
9039457	Expression and distribution of vascular endothelial growth factor protein in human brain tumors.	Acta Neuropathol	1997
9229142	Advances in the molecular genetics of gliomas.	Curr Opin Oncol	1997
9366518	Functional analysis of wild-type and malignant glioma derived CDKN2Abeta alleles: evidence for an RB-independent growth suppressive pathway.	Oncogene	1997
9356475	Growth suppression of glioma cells by PTEN requires a functional phosphatase catalytic domain.	Proc Natl Acad Sci U S A	1997
9342366	Intracerebral tumor-associated hemorrhage caused by overexpression of the vascular endothelial growth factor isoforms VEGF121 and VEGF165 but not VEGF189.	Proc Natl Acad Sci U S A	1997
9006938	The enhanced tumorigenic activity of a mutant epidermal growth factor receptor common in human cancers is mediated by threshold levels of constitutive tyrosine phosphorylation and unattenuated signaling.	J Biol Chem	1997
9053859	Point mutations can inactivate in vitro and in vivo activities of p16(INK4a)/CDKN2A in human glioma.	Oncogene	1997
8625319	Silencing of p16/CDKN2 expression in human gliomas by methylation and chromatin condensation.	Cancer Res	1996
8895767	A common mutant epidermal growth factor receptor confers enhanced tumorigenicity on human glioblastoma cells by increasing proliferation and reducing apoptosis.	Cancer Res	1996
8817614	Molecular biology of malignant degeneration of astrocytoma.	Pediatr Neurosurg	1996
8810340	Enhanced tumorigenic behavior of glioblastoma cells expressing a truncated epidermal growth factor receptor is mediated through the Ras-Shc-Grb2 pathway.	J Biol Chem	1996
8752145	Tyrphostin AG 1478 preferentially inhibits human glioma cells expressing truncated rather than wild-type epidermal growth factor receptors.	Cancer Res	1996
8806451	cAMP effects on myogenic gene expression in rhabdomyosarcoma cells.	Exp Cell Res	1996
8710899	Suppression of glioblastoma angiogenicity and tumorigenicity by inhibition of endogenous expression of vascular endothelial growth factor.	Proc Natl Acad Sci U S A	1996
7862624	Single cell monitoring of growth arrest and morphological changes induced by transfer of wild-type p53 alleles to glioblastoma cells.	Proc Natl Acad Sci U S A	1995
8718522	Genetics and malignant progression of human brain tumours.	Cancer Surv	1995
8586466	The p53 gene and its role in human brain tumors.	Glia	1995
7882335	Replacement of the p16/CDKN2 gene suppresses human glioma cell growth.	Cancer Res	1995

1 - 50 of 53

Khatri Latha

Baylor College of Medicine

Career Start Year 2005

Number of shared co-authors 3

Anita B Hjelmeland

University of Alabama at Birmingham

Career Start Year 2004

Number of shared co-authors 0

Massimo Squatrito

Seve Ballesteros Foundation Brain Tumor group

Career Start Year 2002

Number of shared co-authors 1

Jeongwu Lee

Lerner Research Institute, Cleveland Clinic

Career Start Year 2001

Number of shared co-authors 0

Timothy E Van Meter

Virginia Commonwealthy University

Career Start Year 1998

Number of shared co-authors 1

Krishna P Bhat

Department of Neurosurgery at the University of Texas MD Anderson Cancer Center

Career Start Year 1998

Number of shared co-authors 3

Ian D Clarke

Arthur and Sonia Labatt Brain Tumour Research Centre, The Hospital for Sick Children

Career Start Year 1997

Number of shared co-authors 0

Dimpy Koul

The University of Texas MD Anderson Cancer Center

Career Start Year 1996

Number of shared co-authors 1

Vinay K Puduvalli

The University of Texas MD Anderson Cancer Center

Career Start Year 1996

Number of shared co-authors 1

Christopher Ryan Miller

University of Illinois at Urbana-Champaign

Career Start Year 1996

Number of shared co-authors 5

Kan V Lu

Clinical Medical Research Center of Hepatic Surgery at Hubei Province

Career Start Year 1995

Number of shared co-authors 4

Gurpreet S Kapoor

Collegeville

Career Start Year 1995

Number of shared co-authors 1

Paul S Mischel

Stanford University

Career Start Year 1994

Number of shared co-authors 4

Jeremy N Rich

UPMC Hillman Cancer Center, University of Pittsburgh Medical Center

Career Start Year 1992

Number of shared co-authors 8

Seiji Kondo

Fukuoka University

Career Start Year 1992

Number of shared co-authors 1

Donald M O'Rourke

Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania

Career Start Year 1991

Number of shared co-authors 3

Howard A Fine

Meyer Cancer Center

Career Start Year 1990

Number of shared co-authors 2

Candelaria Gomez-Manzano

The University of Texas M.D. Anderson Cancer Center

Career Start Year 1990

Number of shared co-authors 0

Antonio Iavarone

Sylvester Comprehensive Cancer Center, Miller School of Medicine, University of Miami

Career Start Year 1989

Number of shared co-authors 4

Wei Zhang

The University of Texas MD Anderson Cancer Center

Career Start Year 1988

Number of shared co-authors 3

Guido Reifenberger

Heinrich Heine University

Career Start Year 1987

Number of shared co-authors 6

Juan Fueyo

The University of Texas M.D. Anderson Cancer Center

Career Start Year 1987

Number of shared co-authors 2

Kenneth Aldape

National Cancer Institute

Career Start Year 1985

Number of shared co-authors 10

William A Weiss

University of California san francisco

Career Start Year 1985

Number of shared co-authors 6

Frederick F Lang

The University of Texas M.D. Anderson Cancer Center

Career Start Year 1984

Number of shared co-authors 6

Joshua B Rubin

Washington University in St. Louis

Career Start Year 1983

Number of shared co-authors 1

Gaetano Finocchiaro

IRCCS San Raffaele Scientific Institute

Career Start Year 1983

Number of shared co-authors 7

Wai-Kwan Alfred Yung

University of Texas M.D. Anderson Cancer Center

Career Start Year 1974

Number of shared co-authors 6

George Yancey Gillespie

Heersink School of Medicine, The University of Alabama at Birmingham

Career Start Year 1970

Number of shared co-authors 2

Vincent Peter Collins

Mount Sinai Hospital

Career Start Year 1943

Number of shared co-authors 4

row(s) 1 - 30 of 30

Webster K Cavenee

Ludwig Institute for Cancer Research, University of California San Diego

Co-authored papers 49

Motoo Nagane

Kyorin University Faculty of Medicine

Co-authored papers 16

Frank B Furnari

University of California San Diego

Co-authored papers 11

Oliver B??gler

American Association for Cancer Research, Henry Ford Hospital, Ludwig Institute for Cancer Research, National Cancer Institute, Salk Institute for Biological Studies, University of Cambridge, University of Texas MD Anderson Cancer Center, Virginia Commonwealth University

Co-authored papers 6

Ryo Nishikawa

Saitama Medical University International Medical Center

Co-authored papers 6

Wadih Arap

Rutgers Cancer Institute of New Jersey

Co-authored papers 5

H Lin

Co-authored papers 5

Shi-Yuan Cheng

Northwestern University Feinberg School of Medicine

Co-authored papers 5